HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, Jan. 6, 2021 (HealthDay News) -- Researchers say a new study may offer hope for future patients with glioblastoma, an aggressive brain cancer. It's the brain tumor that killed Senators John McCain and Ted Kennedy.
Investigators from the University of Toronto discovered that the healing process after a brain injury could spur tumor growth if new cells meant to replace those lost in the injury were derailed by mutations.
The findings could lead to new therapies for glioblastoma patients, according to the researchers. Glioblastoma patients currently have limited treatment options and typically survive only 15 months after diagnosis, on average.
"Our data suggest that the right mutational change in particular cells in the brain could be modified by injury to give rise to a tumor," said lead researcher Dr. Peter Dirks, head of the Division of Neurosurgery and a senior scientist in the Developmental and Stem Cell Biology program at Toronto's Hospital for Sick Children.
"Glioblastoma can be thought of as a wound that never stops healing," Dirks said in a university news release. "We're excited about what this tells us about how cancer originates and grows, and it opens up entirely new ideas about treatment by focusing on the injury and inflammation response."
The researchers applied the latest RNA sequencing and machine-learning technologies to map the molecular makeup of glioblastoma stem cells.
They found new subpopulations of glioblastoma stem cells that had the molecular hallmarks of inflammation and were co-mingled with other cancer stem cells inside patients' tumors.
Dirks said this suggests that some glioblastomas start to form when the normal tissue healing process gets derailed by mutations, possibly even many years before a patient has symptoms.
A brain injury can include trauma, infection or stroke. Once a mutant cell becomes engaged in wound healing, it cannot stop multiplying because the normal controls are broken.
"The goal is to identify a drug that will kill the glioblastoma stem cells," said Gary Bader, a professor of molecular genetics in the university's Donnelly Centre for Cellular and Biomolecular Research. "But we first needed to understand the molecular nature of these cells in order to be able to target them more effectively."
Researchers collected glioblastoma stem cells from 26 patients' tumors. They expanded them in the lab, analyzing nearly 70,000 cells by single-cell RNA sequencing. This detects what genes are switched on in individual cells.
The data confirmed that each tumor contains multiple subpopulations of molecularly distinct cancer stem cells. That makes recurrence likely.
Researchers identified two molecular states -- "developmental" or "injury response" -- or somewhere between the two. They said the injury response state was a surprise. Immune signatures in the injury response were only picked up by new single-cell technology after being missed by older methods.
It was also determined that each tumor was biased either toward the developmental or the injury response end of the gradient and the two states were vulnerable in different ways.
"We're now looking for drugs that are effective on different points of this gradient," said Trevor Pugh, senior scientist at the Princess Margaret Cancer Centre. "There's a real opportunity here for precision medicine -- to dissect patients' tumors at the single cell level and design a drug cocktail that can take out more than one cancer stem cell subclone [a clone selected from a clone, especially after a mutation occurs] at the same time."
The research was published Jan. 4 in the journal Nature Cancer.
The American Association of Neurological Surgeons has more on glioblastoma.
SOURCE: University of Toronto, news release, Jan. 4, 2021
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 25, 2022